Literature DB >> 17628332

Diagnosis and management of cholestatic liver disease.

E Jenny Heathcote1.   

Abstract

Cholestasis (slowing of bile flow) may be acute or chronic and affect any age group. In infants and children the causes often are congenital or inherited and as a result of improved management some affected children now survive to adulthood. Although jaundice is a hallmark of cholestasis it may be absent, particularly in adults with chronic cholestatic liver disease most of whom are entirely asymptomatic. A detailed history and physical are crucial to the diagnosis and noninvasive radiologic tests (ultrasound, computerized tomography scan, and magnetic resonance cholangiography) greatly facilitate diagnosis, particularly when the cause is extrahepatic. Only if sufficient portal tracts (>10) are present on liver biopsy examination can this test reliably evaluate damage to the small bile ducts. Therapy should address both the cause and the consequences of retained bile acids within the liver, and diminished delivery of bile to the gastrointestinal tract. Therapies should address symptoms, mostly pruritus and prevention, particularly osteoporosis and osteomalacia. Portal hypertension can be an early event in chronic cholestatic liver disease, sometimes occurring before the development of cirrhosis. Ursodeoxycholic acid improves the biochemical markers of cholestasis regardless of cause and may delay liver disease progression; only liver transplant is potentially curative.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17628332     DOI: 10.1016/j.cgh.2007.05.008

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  11 in total

1.  A man with new onset of ascites and edema.

Authors:  Melvin Lau
Journal:  Medscape J Med       Date:  2008-04-09

2.  D-chiro-inositol effectively attenuates cholestasis in bile duct ligated rats by improving bile acid secretion and attenuating oxidative stress.

Authors:  Shuang-Shuang Zhao; Na-Ren Li; Wu-Li Zhao; Hong Liu; Mao-Xu Ge; Yi-Xuan Zhang; Long-Yin Zhao; Xue-Fu You; Hong-Wei He; Rong-Guang Shao
Journal:  Acta Pharmacol Sin       Date:  2017-07-27       Impact factor: 6.150

3.  Baohuoside I inhibits FXR signaling pathway to interfere with bile acid homeostasis via targeting ER α degradation.

Authors:  Zhen Zhao; Lu-Lu Yang; Qiao-Lei Wang; Jin-Fa Du; Zu-Guo Zheng; Yan Jiang; Ping Li; Hui-Jun Li
Journal:  Cell Biol Toxicol       Date:  2022-07-08       Impact factor: 6.691

4.  Prevention of Cell Growth by Suppression of Villin Expression in Lithocholic Acid-Stimulated HepG2 Cells.

Authors:  Munetaka Ozeki; Wulamujiang Aini; Aya Miyagawa-Hayashino; Keiji Tamaki
Journal:  J Histochem Cytochem       Date:  2018-10-10       Impact factor: 2.479

5.  A Predictive 3D Multi-Scale Model of Biliary Fluid Dynamics in the Liver Lobule.

Authors:  Kirstin Meyer; Oleksandr Ostrenko; Georgios Bourantas; Hernan Morales-Navarrete; Natalie Porat-Shliom; Fabian Segovia-Miranda; Hidenori Nonaka; Ali Ghaemi; Jean-Marc Verbavatz; Lutz Brusch; Ivo Sbalzarini; Yannis Kalaidzidis; Roberto Weigert; Marino Zerial
Journal:  Cell Syst       Date:  2017-03-18       Impact factor: 10.304

6.  Prospective evaluation of the diagnostic accuracy of hepatic copper content, as determined using the entire core of a liver biopsy sample.

Authors:  Xu Yang; Xiao-peng Tang; Yong-hong Zhang; Kai-zhong Luo; Yong-fang Jiang; Hong-yu Luo; Jian-hua Lei; Wen-long Wang; Ming-ming Li; Han-chun Chen; Shi-lin Deng; Li-ying Lai; Jun Liang; Min Zhang; Yi Tian; Yun Xu
Journal:  Hepatology       Date:  2015-08-27       Impact factor: 17.425

7.  Heparin-binding epidermal growth factor-like growth factor and hepatocyte growth factor inhibit cholestatic liver injury in mice through different mechanisms.

Authors:  Kouichi Sakamoto; Ngin Cin Khai; Yuqing Wang; Rie Irie; Hideo Takamatsu; Hiroshi Matsufuji; Ken-Ichiro Kosai
Journal:  Int J Mol Med       Date:  2016-10-20       Impact factor: 4.101

Review 8.  Primary biliary cirrhosis.

Authors:  Simon Hohenester; Ronald P J Oude-Elferink; Ulrich Beuers
Journal:  Semin Immunopathol       Date:  2009-07-15       Impact factor: 9.623

9.  Mitochondrial Mutations in Cholestatic Liver Disease with Biliary Atresia.

Authors:  Hong Koh; Gun-Seok Park; Sun-Mi Shin; Chang Eon Park; Seung Kim; Seok Joo Han; Huy Quang Pham; Jae-Ho Shin; Dong-Woo Lee
Journal:  Sci Rep       Date:  2018-01-17       Impact factor: 4.379

10.  Circulating FGF19 closely correlates with bile acid synthesis and cholestasis in patients with primary biliary cirrhosis.

Authors:  Zhanyi Li; Bingliang Lin; Guoli Lin; Yuankai Wu; Yusheng Jie; Xiangyong Li; Brian Ko; Yutian Chong; Jian Luo
Journal:  PLoS One       Date:  2017-06-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.